EMA rejects claims of undue industry influence on data disclosure policy
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has dismissed suggestions that the 2013 appointment of a new head of legal services with an industry background had a significant influence on the development of its draft policy on clinical trial data disclosure. It has also sharply rejected the idea that it does not pay sufficient attention to the interests of patients.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.